Drugs that contain Testosterone Enanthate
1. List of Xyosted (autoinjector) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8562564 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US11446441 | ANTARES PHARMA INC | Prefilled syringe injector |
Jan, 2026
(2 years from now) | |
| US9533102 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US9180259 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US9629959 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US10478560 | ANTARES PHARMA INC | Prefilled syringe injector |
Jan, 2026
(2 years from now) | |
| US8021335 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Oct, 2026
(3 years from now) | |
| US11497753 | ANTARES PHARMA INC | Hazardous agent injection system |
Mar, 2030
(7 years from now) | |
| US10279131 | ANTARES PHARMA INC | Injection device with cammed RAM assembly |
Jul, 2031
(8 years from now) | |
| US11446440 | ANTARES PHARMA INC | Needle assisted injection device having reduced trigger force |
Aug, 2031
(8 years from now) | |
| US10357609 | ANTARES PHARMA INC | Needle assisted jet injection device having reduced trigger force |
Aug, 2031
(8 years from now) | |
| US10905827 | ANTARES PHARMA INC | Injection device with cammed ram assembly |
Aug, 2031
(8 years from now) | |
| US10821072 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Jun, 2033
(10 years from now) | |
| US10881798 | ANTARES PHARMA INC | Needle assisted injection device having reduced trigger force |
Feb, 2034
(11 years from now) | |
| US11160751 | ANTARES PHARMA INC | Hematocrit modulation through needle assisted jet injection of testosterone |
Oct, 2034
(11 years from now) | |
| US10238662 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Feb, 2035
(12 years from now) | |
| US10912782 | ANTARES PHARMA INC | Needle assisted injection administration of testosterone compositions |
Feb, 2035
(12 years from now) | |
| US11191908 | ANTARES PHARMA INC | Syringe shock absorber for use in an injection device |
Oct, 2035
(12 years from now) | |
| US9744302 | ANTARES PHARMA INC | Needle assisted jet injection device having reduced trigger force |
Nov, 2035
(12 years from now) | |
| US9950125 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Sep, 2036
(13 years from now) | |
| US10646495 | ANTARES PHARMA INC | Testosterone ester triglyceride formulations |
Aug, 2038
(15 years from now) | |
Market Authorisation Date: 28 September, 2018
Treatment: Method of administering testosterone enanthate subcutaneously
Dosage: SOLUTION;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic